Selenium-containing polysaccharides from Lentinula edodes-Biological activity.
Clicks: 229
ID: 46988
2019
Article Quality & Performance Metrics
Overall Quality
Improving Quality
0.0
/100
Combines engagement data with AI-assessed academic quality
Reader Engagement
Steady Performance
71.8
/100
229 views
183 readers
Trending
AI Quality Assessment
Not analyzed
Abstract
We hypothesized that selenium(Se)-enriched polysaccharides would possess superior biological activity when compared to those non-enriched. To verify this hypothesis, we obtained by biotechnological methods a Se-enriched analog of Japanese anticancer drug lentinan and, as a reference, the non-Se-enriched fraction. We tested the effects of the obtained fractions on the proliferation of human peripheral blood mononuclear cells. The results suggested a selective immunosuppressive activity, non-typical for mushroom derived polysaccharides. Both fractions caused significant inhibition of human T lymphocyte proliferation induced by mitogens, without significant effects on B lymphocytes. The inhibitory effect was not due to the toxicity of the examined polysaccharides. In normal (HUVEC) or malignant (HeLa) cells tested fractions significantly enhanced cell viability and protected the cells from oxidative stress conditions. However, we observed no effect of the polysaccharide fractions on the production of reactive oxygen species by granulocytes in vitro. The selenium content increased the biological activity of the tested polysaccharide fractions.Reference Key |
kaleta2019seleniumcontainingcarbohydrate
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
---|---|
Authors | Kaleta, Beata;Górski, Andrzej;Zagożdżon, Radosław;Cieślak, Marcin;Kaźmierczak-Barańska, Julia;Nawrot, Barbara;Klimaszewska, Marzenna;Malinowska, Eliza;Górska, Sandra;Turło, Jadwiga; |
Journal | Carbohydrate polymers |
Year | 2019 |
DOI | S0144-8617(19)30745-3 |
URL | |
Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.